1.Cancer discoveryPolyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma."37722 was used in ELISA to determine the molecular basis for acquired resistance to the fibroblast growth factor receptor inhibitor BGJ398"AuthorsGoyal L,Saha SK,Liu LY,Siravegna G,Leshchiner I,Ahronian LG,Lennerz JK,Vu P,Deshpande V,Kambadakone A,Mussolin B,Reyes S,Henderson L,Sun JE,Van Seventer EE,Gurski JM,Baltschukat S,Schacher-Engstler B,Barys L,Stamm C,Furet P,Ryan DP,Stone JR,Iafrate AJ,Getz G,Porta DG,Tiedt R,Bardelli A,Juric D,Corcoran RB,Bardeesy N,Zhu AX2.European journal of haematologyPhosphorylation of Tyr245 in the open-inhibited state of Abelson kinase does not induce downstream signaling."03-7722 was used in ELISA to investigate the role of Tyr245 phosphorylation in Abelson kinase function"AuthorsSkora L,Kempf D,Mestan J,D'Orazio D,Jahnke W3.Proceedings of the National Academy of Sciences of the United States of AmericaNMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors."03-7722 was used in an ELISA assay to analyse the solution conformations of Abelson tyrosine kinase (c-Abl) and c-Abl complexes with ATP-site and allosteric inhibitors."AuthorsSkora L,Mestan J,Fabbro D,Jahnke W,Grzesiek S4.AngiogenesisThe small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis."03-7722 was used in ELISA to develop and characterize an inhibitor of EphB4 kinase"5.CancersIncreased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor."03-7722 was used in an ELISA assay to study the link between SH2 domain-containing adaptor protein activation, the estrogen receptor, and primary breast cancer prognosis."AuthorsCicenas J,Küng W,Eppenberger U,Eppenberger-Castori S |